Focus area
Bio-convergence
Evolving biotech into an engineering discipline at the intersection of AI, hardware, and biology.
Celesta Capital invests in bio-convergence: compute, sensing, automation, and data science applied to improve scale and predictability in diagnostics, imaging, care delivery, and drug discovery.
Portfolio
- 1Cell.Ai: A genomics-based Precision Oncology company.
- 5C Network: Teleradiology platform connecting hospitals with on-demand radiologist reporting.
- Alveo: Molecular diagnostic platform for rapid detection of infectious diseases.
- Astranu: Next-generation ear imaging technology for clinical and consumer ear care.
- Prellis: 3D printing of synthetic human tissues to advance drug discovery and development.
- WhiteRabbit.ai: AI-driven imaging software for earlier breast cancer detection.
IPOs and exits
- Berkeley Lights (IPO): Optofluidic platform for single-cell biology and biologics discovery.
- Atonarp (exited): Miniaturized mass and optical spectrometry for clinical and industrial sensing.